Trial reportNature medicine2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
Erratum issued Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05235737 (A Single Center, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of Neoadjuvant and Adjuvant Pembrolizumab on Top of Standard Chemo-Radiotherapy), which is not on this map. Cited by 486 papers, 10 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
486citing papers in PubMed, 10 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single Center, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of Neoadjuvant and Adjuvant Pembrolizumab on Top of Standard Chemo-Radiotherapy (Stupp Protocol) in Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme (GBM).
Who cites it
486 citing papers in PubMed, 10 syntheses or guidelines pooled it.
- Cancer-related fatigue during treatment with neoadjuvant and/or adjuvant immune checkpoint inhibitors: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- A comprehensive review and case series of adjuvant and neoadjuvant therapies in acral melanoma with emerging insights from CT DNA testing.Frontiers in oncology · 2025Pooled it
- Efficacy of Immune Checkpoint Inhibitors in the Treatment for Head and Neck Cancer Patients: A Systematic Review and Network Meta-Analysis.Oncology research · 2025Pooled it
- Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis.JAMA oncology · 2024Pooled it
- Research hotspots and trend of glioblastoma immunotherapy: a bibliometric and visual analysis.Frontiers in oncology · 2024Pooled it
- Evaluating the efficacy and safety of different neoadjuvant immunotherapy combinations in locally advanced HNSCC: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis.World journal of surgical oncology · 2023Pooled it
- Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2023Pooled it
- Tumour-infiltrating lymphocytes: from prognosis to treatment selection.British journal of cancer · 2023Pooled it
- Neoadjuvant treatment for stage III and IV cutaneous melanoma.The Cochrane database of systematic reviews · 2023Pooled it
- Axitinib plus Avelumab in Recurrent/Metastatic Adenoid Cystic Carcinoma: Biomarker Analysis and Updated Results of the Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- CD8 PET imaging with [Journal for immunotherapy of cancer · 2026Trial
- Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.Nature medicine · 2026Trial
- Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.Nature cancer · 2026Trial
- Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.Nature medicine · 2025Trial
- Economic Evaluation of Inguinal Versus Ilio-inguinal Lymphadenectomy for Patients with Stage III Metastatic Melanoma to Groin Lymph Nodes: Evidence from the EAGLE FM Randomized Trial.Annals of surgical oncology · 2025Trial
- Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.Journal for immunotherapy of cancer · 2025Trial
- Distinct CD8Cancer cell · 2025Trial
- Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.Cancer cell · 2024Trial
- Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFNature medicine · 2024Trial
426 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
- Erratum issued
Authors and funding
45 authors.
Rodabe N AmariaDepartment of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6876-278X
Sangeetha M ReddyDepartment of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Hussein A TawbiDepartment of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Michael A DaviesDepartment of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-0977-0912
Merrick I RossDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Isabella C GlitzaDepartment of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Janice N CormierDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Carol LewisDepartment of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA.
Wen-Jen HwuDepartment of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Ehab HannaDepartment of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA.
Adi DiabDepartment of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Michael K WongDepartment of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Richard RoyalDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Neil GrossDepartment of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-9427-0743
Randal WeberDepartment of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA.
Stephen Y LaiDepartment of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA.
Richard EhlersDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Jorge BlandoDepartment of Immunology, MD Anderson Cancer Center, Houston, TX, USA.
Denái R MiltonDepartment of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA.
Scott WoodmanDepartment of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Robin KageyamaParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Daniel K WellsParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Patrick HwuDepartment of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Sapna P PatelDepartment of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Anthony LucciDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Amy HesselDepartment of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA.
Jeffrey E LeeDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Jeffrey GershenwaldDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Lauren SimpsonDepartment of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Elizabeth M BurtonDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Liberty PosadaDepartment of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Lauren HayduDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Linghua WangDepartment of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9380-0266
Shaojun ZhangDepartment of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA.
Alexander J LazarDepartment of Pathology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6395-4499
Courtney W HudgensDepartment of Pathology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8312-7485
Vancheswaran GopalakrishnanDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Alexandre ReubenDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-4510-0382
Miles C AndrewsDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Christine N SpencerDepartment of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA.
Victor PrietoDepartment of Pathology, MD Anderson Cancer Center, Houston, TX, USA.
Padmanee SharmaDepartment of Immunology, MD Anderson Cancer Center, Houston, TX, USA.
James AllisonDepartment of Immunology, MD Anderson Cancer Center, Houston, TX, USA.
Michael T TetzlaffDepartment of Pathology, MD Anderson Cancer Center, Houston, TX, USA.
Jennifer A WargoDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.
Funding
Center for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4MTRAINING FOR ACADEMIC ONCOLOGY/HEMATOLOGYT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, Courtney DiNardo · 1994 to 2026
$9.8MExploring synergy of combined BRAF-targeted therapy & immunotherapy for melanomaK08CA160692 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WARGO, JENNIFER A. · 2012 to 2016
$713kNCATS NIH HHS UL1 TR000371NCI NIH HHS K08 CA160692NCI NIH HHS T32 CA009666
Abstract
Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses compared with adjuvant treatment
Indexed as
Neoadjuvant TherapyAdultAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalDrug-Related Side Effects and Adverse ReactionsFemaleHumansIpilimumabMaleMelanomaMiddle AgedNeoplasm StagingNivolumabRisk FactorsIpilimumabNivolumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05235737ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.